Introduction: CT alone cannot provide sufficient information referring to response after neoadjuvant therapy in a timely manner. To evaluate the role of 18F-FDG-PET after neoadjuvant chemoradiation as a valid, non-inv...Introduction: CT alone cannot provide sufficient information referring to response after neoadjuvant therapy in a timely manner. To evaluate the role of 18F-FDG-PET after neoadjuvant chemoradiation as a valid, non-invasive predictor for early therapy response and its effect on survival as compared to histopathologic tumor response, data of 32 of 210 randomized patients with NSCLC stage IIIA/IIIB, who were treated in a?prospective randomized controlled multicenter trial (LUCAS- MD), were re-evaluated. Material and Methods: For 32 patients with NSCLC stage IIIA (44%) IIIB (56%) neoadjuvant treatment consisted of two to three cycles of chemotherapy (225 mg/m2 paclitaxel and carboplatin AUC 6 d1q22) and concomitant chemoradiation (50 mg/m2 paclitaxel and carboplatin AUC 2 d1, d8, d15;1.5 Gy b.i.d. up to 45 Gy). Documentation of involved lymph node stations as detected by 18F-FDG-PET/CT and lymph node sampling during surgery according to the IASLC lymph node mapping (2009). Evaluation of histological regression grade (RG) according to Junker et al. (2001) and correlation with?18F-FDG-PET/CT for primary tumor and each lymph node station. Calculation of disease free survival using Kaplan-Meier estimates and log rank tests. Results: Actuarial tumor specific survival for the 32 patients with concomitant chemoradiation plus?chemotherapy: complete vs. incomplete metabolic remission prior to surgery after 60 months:?40% vs. 24% (p?= 0.018). RG III/IIb (no/less than 10% of vital tumor cells) vs. RG IIa/I (more than 10% vital tumor cells) after 60 months: 46% vs. 15% (p?= 0.006). 18/32 (56%) patients had RG III/IIb, 8/32 (25%) patients had regression grade III. 1/8 pts. with RG III were in the 18F-FDG- PET/CT false positive, 10 pts. with RG IIb (i.e. all pts. with RG IIb) were in the 18F-FDG-PET/CT false negative. One patient with RG IIa was in the 18F-FDG-PET/CT false negative. Hence, the cut-off level in detecting vital tumor cells by 18F-FDG-PET/CT after neoadjuvant chemoradiation for NSCLC is about 10%. Conclusion: Histological regression grading correlates well with metabolic remission as detected by 18F-FDG-PET. Thus, 18F-FDG-PET precedes CT in measuring the tumor response and may predict long-term therapeutic outcome in patients with stage III NSCLC. Invasive staging procedures may be avoided and patients who will not profit from resection due to insufficient downstaging after neoadjuvant treatment will be easily detected by using 18F-FDG-PET as standard imaging in workup and evaluation of treatment response.展开更多
Objective The purpose of the study was to investigate effective surgical procedure for perirolandic epilepsy and the predictor for good outcomes. Methods We collected 21 subjects who underwent epilepsy surgeries conse...Objective The purpose of the study was to investigate effective surgical procedure for perirolandic epilepsy and the predictor for good outcomes. Methods We collected 21 subjects who underwent epilepsy surgeries consecutively in Beijing Institute of Functional展开更多
Ulcerative colitis(UC) is an immune-mediated, chronic inflammatory disease of the large intestine. Its course is characterized by flares of acute inflammation and periods of low-grade chronic inflammatory activity or ...Ulcerative colitis(UC) is an immune-mediated, chronic inflammatory disease of the large intestine. Its course is characterized by flares of acute inflammation and periods of low-grade chronic inflammatory activity or remission. Monoclonal antibodies against tumor necrosis factor(anti-TNF) are part of the therapeutic armamentarium and are used in cases of moderate to severe UC that is refractory to conventional treatment with corticosteroids and/or immunosuppressants. Therapeutic response to these agents is not uniform and a large percentage of patients either fail to improve(primary non-response) or lose response after a period of improvement(secondary non-response/loss of response). In addition, the use of anti-TNF agents has been related to uncommon but potentially serious adverse effects that preclude their administration or lead to their discontinuation. Finally, use of these medications is associated with a considerable cost for the health system. The identification of parameters thatmay predict response to anti-TNF drugs in UC would help to better select for patients with a high probability to respond and minimize risk and costs for those who will not respond. Analysis of the major clinical trials and the accumulated experience with the use of anti-TNF drugs in UC has resulted to the report of such prognostic factors. Included are clinical and epidemiological characteristics, laboratory markers, endoscopic indicators and molecular(immunological/genetic) signatures. Such predictive parameters of long-term outcomes may either be present at the commencement of treatment or determined during the early period of therapy. Validation of these prognostic markers in large cohorts of patients with variable characteristics will facilitate their introduction into clinical practice and the best selection of UC patients who will benefit from anti-TNF therapy.展开更多
We aim to determine the baseline factors associated with partial and cEVR by analyzing the data of 1861 Egyptian patients treated for 12 weeks with a course of Peg-IFN plus RBV. Base line data of 1861 Egyptian patient...We aim to determine the baseline factors associated with partial and cEVR by analyzing the data of 1861 Egyptian patients treated for 12 weeks with a course of Peg-IFN plus RBV. Base line data of 1861 Egyptian patients with chronic hepatitis C coming at Cairo-Fatemic Hospital for HCV treatment were studied including full clinical, Ultrasonographic examination, laboratory evaluation and liver biopsy. The most significant variables in relation to complete early virological response were low Hb level (13 gm/dl) with p 0.01, the stage of fibrosis p value < 0.05 and the grades of inflammation p value were associated with less achievement of c EVR. We conclude that identifying the most significant predictors of response such as Hb, stage of fibrosis F, at baseline before initiating treatment is mandatory to predict which patient will be more expected to achieve a cEVR and thus reducing the side-effects and healthcare costs associated with interferon therapies.展开更多
目的探索影响轻中度抑郁症患者对电针、药物和针药联合3种不同干预措施应答的关键因素。方法将61例轻中度抑郁症患者随机分为电针组(20例,脱落1例)、药物组(20例,脱落4例)和针药联合组(21例,脱落1例)。电针治疗选取主穴百会、印堂并接电...目的探索影响轻中度抑郁症患者对电针、药物和针药联合3种不同干预措施应答的关键因素。方法将61例轻中度抑郁症患者随机分为电针组(20例,脱落1例)、药物组(20例,脱落4例)和针药联合组(21例,脱落1例)。电针治疗选取主穴百会、印堂并接电,每次30 min,每周3次;药物治疗口服草酸艾司西酞普兰,5~10 mg/d;针药联合组的患者同时接受电针和药物治疗,治疗均持续6周。观察患者抑郁严重程度、生活质量等临床表现,ELISA法检测3组患者血清相关指标表达水平。结果治疗后,3组患者,24项汉密尔顿抑郁量在(24-item Hamilton depression scale,HAMD-24)评分均显著下降(P<0.05),3组患者,健康状况调查问卷(short form 36 health survey,SF-36)评分均显著提高(P<0.05)。3组患者的HAMD-24应答率、缓解率、SSRS、SF-36评分差异无统计学意义(P>0.05)。结合临床症状和分子生物学指标模拟的模型较为可靠。结论适合不同干预措施的轻、中度抑郁症患者人群基本特征有所不同。对伴随较严重睡眠障碍的抑郁症患者,选择针药联合治疗更有可能取得较好的临床疗效。展开更多
文摘Introduction: CT alone cannot provide sufficient information referring to response after neoadjuvant therapy in a timely manner. To evaluate the role of 18F-FDG-PET after neoadjuvant chemoradiation as a valid, non-invasive predictor for early therapy response and its effect on survival as compared to histopathologic tumor response, data of 32 of 210 randomized patients with NSCLC stage IIIA/IIIB, who were treated in a?prospective randomized controlled multicenter trial (LUCAS- MD), were re-evaluated. Material and Methods: For 32 patients with NSCLC stage IIIA (44%) IIIB (56%) neoadjuvant treatment consisted of two to three cycles of chemotherapy (225 mg/m2 paclitaxel and carboplatin AUC 6 d1q22) and concomitant chemoradiation (50 mg/m2 paclitaxel and carboplatin AUC 2 d1, d8, d15;1.5 Gy b.i.d. up to 45 Gy). Documentation of involved lymph node stations as detected by 18F-FDG-PET/CT and lymph node sampling during surgery according to the IASLC lymph node mapping (2009). Evaluation of histological regression grade (RG) according to Junker et al. (2001) and correlation with?18F-FDG-PET/CT for primary tumor and each lymph node station. Calculation of disease free survival using Kaplan-Meier estimates and log rank tests. Results: Actuarial tumor specific survival for the 32 patients with concomitant chemoradiation plus?chemotherapy: complete vs. incomplete metabolic remission prior to surgery after 60 months:?40% vs. 24% (p?= 0.018). RG III/IIb (no/less than 10% of vital tumor cells) vs. RG IIa/I (more than 10% vital tumor cells) after 60 months: 46% vs. 15% (p?= 0.006). 18/32 (56%) patients had RG III/IIb, 8/32 (25%) patients had regression grade III. 1/8 pts. with RG III were in the 18F-FDG- PET/CT false positive, 10 pts. with RG IIb (i.e. all pts. with RG IIb) were in the 18F-FDG-PET/CT false negative. One patient with RG IIa was in the 18F-FDG-PET/CT false negative. Hence, the cut-off level in detecting vital tumor cells by 18F-FDG-PET/CT after neoadjuvant chemoradiation for NSCLC is about 10%. Conclusion: Histological regression grading correlates well with metabolic remission as detected by 18F-FDG-PET. Thus, 18F-FDG-PET precedes CT in measuring the tumor response and may predict long-term therapeutic outcome in patients with stage III NSCLC. Invasive staging procedures may be avoided and patients who will not profit from resection due to insufficient downstaging after neoadjuvant treatment will be easily detected by using 18F-FDG-PET as standard imaging in workup and evaluation of treatment response.
文摘Objective The purpose of the study was to investigate effective surgical procedure for perirolandic epilepsy and the predictor for good outcomes. Methods We collected 21 subjects who underwent epilepsy surgeries consecutively in Beijing Institute of Functional
文摘Ulcerative colitis(UC) is an immune-mediated, chronic inflammatory disease of the large intestine. Its course is characterized by flares of acute inflammation and periods of low-grade chronic inflammatory activity or remission. Monoclonal antibodies against tumor necrosis factor(anti-TNF) are part of the therapeutic armamentarium and are used in cases of moderate to severe UC that is refractory to conventional treatment with corticosteroids and/or immunosuppressants. Therapeutic response to these agents is not uniform and a large percentage of patients either fail to improve(primary non-response) or lose response after a period of improvement(secondary non-response/loss of response). In addition, the use of anti-TNF agents has been related to uncommon but potentially serious adverse effects that preclude their administration or lead to their discontinuation. Finally, use of these medications is associated with a considerable cost for the health system. The identification of parameters thatmay predict response to anti-TNF drugs in UC would help to better select for patients with a high probability to respond and minimize risk and costs for those who will not respond. Analysis of the major clinical trials and the accumulated experience with the use of anti-TNF drugs in UC has resulted to the report of such prognostic factors. Included are clinical and epidemiological characteristics, laboratory markers, endoscopic indicators and molecular(immunological/genetic) signatures. Such predictive parameters of long-term outcomes may either be present at the commencement of treatment or determined during the early period of therapy. Validation of these prognostic markers in large cohorts of patients with variable characteristics will facilitate their introduction into clinical practice and the best selection of UC patients who will benefit from anti-TNF therapy.
文摘We aim to determine the baseline factors associated with partial and cEVR by analyzing the data of 1861 Egyptian patients treated for 12 weeks with a course of Peg-IFN plus RBV. Base line data of 1861 Egyptian patients with chronic hepatitis C coming at Cairo-Fatemic Hospital for HCV treatment were studied including full clinical, Ultrasonographic examination, laboratory evaluation and liver biopsy. The most significant variables in relation to complete early virological response were low Hb level (13 gm/dl) with p 0.01, the stage of fibrosis p value < 0.05 and the grades of inflammation p value were associated with less achievement of c EVR. We conclude that identifying the most significant predictors of response such as Hb, stage of fibrosis F, at baseline before initiating treatment is mandatory to predict which patient will be more expected to achieve a cEVR and thus reducing the side-effects and healthcare costs associated with interferon therapies.
文摘目的探讨稳定型胸腰椎爆裂骨折(thoracolumbar burst fractures,TBF)非手术治疗的失败率和预测因素。方法选择2015年1月~2020年12月在该院接受非手术治疗的稳定型TBF患者资料进行回顾性分析,记录患者非手术治疗失败率。观察非手术治疗失败和非手术治疗成功患者的性别、年龄、体质量指数(body mass index,BMI)、个人史、伴随疾病、损伤原因、损伤椎体、疼痛视觉模拟评分(visual analogue scale,VAS)、椎体压缩率(vertebral body compression rate,VBCR)、椎体前缘高度压缩百分比(percentage anterior high compression,PAHC)、Cobb角、椎弓根间距(interpedicular distance,IPD)和椎管压缩程度,采用Logistic回归分析确定影响非手术治疗效果的独立因素。结果71例患者有21例非手术治疗失败,发生率29.58%。非手术治疗失败患者年龄、BMI、糖尿病、VBCR、PAHC、Cobb角、IPD、椎管压缩和VAS均高于非手术治疗成功患者(P<0.05)。多因素Logistic回归分析结果显示,年龄和IPD是影响非手术治疗效果的独立风险因素(P<0.05)。年龄预测非手术治疗失败的灵敏度、特异性、截断值和AUC分别为71.40%、86.00%、47岁、0.811,IPD预测非手术治疗失败的灵敏度、特异性、截断值和AUC分别为71.43%、88.00%、16.7%和0.771。结论年龄和IPD是影响稳定型TBF患者非手术治疗失败的风险因素,对预测手术失败具有一定临床价值。
文摘目的探索影响轻中度抑郁症患者对电针、药物和针药联合3种不同干预措施应答的关键因素。方法将61例轻中度抑郁症患者随机分为电针组(20例,脱落1例)、药物组(20例,脱落4例)和针药联合组(21例,脱落1例)。电针治疗选取主穴百会、印堂并接电,每次30 min,每周3次;药物治疗口服草酸艾司西酞普兰,5~10 mg/d;针药联合组的患者同时接受电针和药物治疗,治疗均持续6周。观察患者抑郁严重程度、生活质量等临床表现,ELISA法检测3组患者血清相关指标表达水平。结果治疗后,3组患者,24项汉密尔顿抑郁量在(24-item Hamilton depression scale,HAMD-24)评分均显著下降(P<0.05),3组患者,健康状况调查问卷(short form 36 health survey,SF-36)评分均显著提高(P<0.05)。3组患者的HAMD-24应答率、缓解率、SSRS、SF-36评分差异无统计学意义(P>0.05)。结合临床症状和分子生物学指标模拟的模型较为可靠。结论适合不同干预措施的轻、中度抑郁症患者人群基本特征有所不同。对伴随较严重睡眠障碍的抑郁症患者,选择针药联合治疗更有可能取得较好的临床疗效。
